Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.53 |
| ▸ | CCR4 | P51679 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 4/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.45 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | GLA | P06280 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | CASP1 | P29466 | 3/20 | 0.43 |
| ▸ | CASP7 | P55210 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL961248 | 0.75 | HSD17B3 (0.55) | HSD17B3ESR1ESR2ERAP1NPC1 | |
| SCHEMBL12521082 | 0.74 | HSD17B3 (0.53) | HSD17B3ESR1ESR2ERAP1NPC1 | |
| SCHEMBL6907581 | 0.72 | HSD17B3 (0.75) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| SCHEMBL27817043 | 0.72 | HSD17B3 (0.65) | HSD17B3ESR1ESR2ERAP1NPC1 | |
| SCHEMBL15950101 | 0.72 | HSD17B3 (0.65) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| SCHEMBL591899 | 0.72 | HSD17B3 (1.00) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| SCHEMBL31366988 | 0.72 | HSD17B3 (1.00) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| Hydrochloric Acid SCHEMBL961541 | 0.71 | HSD17B3 (0.73) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| SCHEMBL194511 | 0.71 | HSD17B3 (0.63) | HSD17B3CCR4ESR1ESR2ERAP1 | |
| SCHEMBL30763746 | 0.71 | HSD17B3 (0.63) | HSD17B3CCR4ESR1ESR2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172198-B1 | p27 PROTEIN INDUCER | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8569378-B2 | p27 protein inducer | Sakai, Toshiyuki (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8278465-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-02 | — | — | US | disclosed |
| EP-1982982-B1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | IIKURA HITOSHI | 2011-04-21 | — | — | US | disclosed |
| US-7897792-B2 | Coumarin derivative having antitumor activity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | disclosed |
| US-20110009398-A1 | p27 Protein Inducer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2172198-A1 | p27 PROTEIN INDUCER | Chugai Seiyaku Kabushiki Kaisha (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-1982982-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009398-A1 | p27 Protein Inducer | CDKN1A, CDK2, SKP2 | HSD17B3 2321/4885CCR4 4036/4885ESR1 547/4885 |
| US-20110092700-A1 | Novel Coumarin Derivative Having Antitumor Activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | HSD17B3 704/4885CCR4 1373/4885ESR1 2405/4885 |
| US-20100004233-A1 | NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SULT1A1, SULT1E1 | HSD17B3 704/4885CCR4 1373/4885ESR1 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.